Does RITUXIMAB Cause Second primary malignancy? 646 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 646 reports of Second primary malignancy have been filed in association with RITUXIMAB (Rituxan). This represents 0.4% of all adverse event reports for RITUXIMAB.
646
Reports of Second primary malignancy with RITUXIMAB
0.4%
of all RITUXIMAB reports
255
Deaths
91
Hospitalizations
How Dangerous Is Second primary malignancy From RITUXIMAB?
Of the 646 reports, 255 (39.5%) resulted in death, 91 (14.1%) required hospitalization, and 64 (9.9%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
Yes, Second primary malignancy is listed as a known adverse reaction in the official FDA drug label for RITUXIMAB.
What Other Side Effects Does RITUXIMAB Cause?
Off label use (39,751)
Drug ineffective (32,186)
Rheumatoid arthritis (19,850)
Pain (16,675)
Fatigue (15,602)
Arthralgia (12,529)
Rash (12,102)
Drug intolerance (11,876)
Infusion related reaction (11,871)
Joint swelling (11,170)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
METHOTREXATE (414)
Which RITUXIMAB Alternatives Have Lower Second primary malignancy Risk?
RITUXIMAB vs RITUXIMAB-ABBS
RITUXIMAB vs RITUXIMAB-ARRX
RITUXIMAB vs RITUXIMAB-PVVR
RITUXIMAB vs RIVAROXABAN
RITUXIMAB vs RIVASTIGMINE